Every material Form 8-K Arrowhead Pharmaceuticals filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Arrowhead Pharmaceuticals refinanced its senior secured term loans on November 2, 2026, replacing a 15.0% payment-in-kind facility with a $400.0 million term loan at three-month Term SOFR plus 5.50% that matures November 2, 2031. The existing loans were repaid in full from cash on hand for an aggregate payoff of approximately $404.4 million, a discount of about $68 million from the 2.0x MOIC payment otherwise owed, and the new terms remove required prepayments from plozasiran sales and licensing proceeds. For shareholders, the filing shows lower interest cost, a longer maturity and fewer mandatory repayments, while the company now carries a $400.0 million secured obligation.
New $400.0 million senior secured term loan matures November 2, 2031, with interest at three-month Term SOFR (1.00% floor) plus 5.50%, versus a fixed 15.0% rate paid in kind on the retired loans
Existing loans repaid in full from cash on hand for an aggregate payoff of approximately $404.4 million, which included a discount of about $68 million from the 2.0x MOIC payment
Minimum unrestricted cash covenant reduced to $125.0 million from $150.0 million
New agreement no longer requires prepayment from plozasiran sales, royalties, milestones or pipeline monetizations; the filing says the terms are to be filed with the 10-Q for the quarter ended December 31, 2026
Arrowhead Pharmaceuticals reported fiscal third-quarter 2026 results for the period ended June 30, 2026. Revenue rose to $75.3 million from $27.8 million a year earlier, but the net loss attributable to Arrowhead widened to $194.3 million, or $1.36 per diluted share, from $175.2 million, or $1.26 per share, as research and development and selling, general and administrative expenses increased.
Revenue was $75.3 million for the quarter, compared with $27.8 million in the prior-year quarter.
Net loss attributable to Arrowhead was $194.3 million, or $1.36 per diluted share, versus $175.2 million, or $1.26 per share, a year earlier.
Research and development expense was $198.2 million, up from $162.4 million, and SG&A expense was $47.1 million, up from $30.9 million.
Total cash resources were $1.57 billion at June 30, 2026, compared with $781.5 million at September 30, 2025.
Arrowhead Pharmaceuticals appointed Dr. Matt Cohen as a director effective June 12, 2026, as disclosed in a June 16, 2026 Form 8-K. Dr. Cohen previously spent about two decades in healthcare investing and portfolio management, most recently as Managing Director at Vida Ventures, and his board seat adds a director with healthcare investment experience.
Board appointment effective June 12, 2026
Dr. Cohen is Managing Director at Vida Ventures and previously served at JP Morgan Asset Management from 2005
Sign-on grant of restricted stock units valued at $887,000, scheduled to vest over three years
Dr. Cohen will receive standard non-employee director compensation and enter the Company's standard indemnity agreement
Arrowhead Pharmaceuticals reported fiscal second-quarter results for the period ended March 31, 2026, with revenue of $73.7 million, down from $542.7 million a year earlier. The company posted a net loss attributable to Arrowhead of $132.7 million, or $0.93 per diluted share, compared with net income of $370.4 million, or $2.75 per diluted share, a year earlier. The filing also cites two concurrent public offerings with gross proceeds totaling $930 million.
Revenue was $73.7 million for the quarter, versus $542.7 million in the same period a year earlier.
Net loss attributable to Arrowhead was $132.7 million, or $0.93 per diluted share, versus net income of $370.4 million, or $2.75 per diluted share.
Two concurrent offerings raised $930 million gross, including $700 million of 0.00% convertible senior notes due 2032 and $230 million of common stock at $64.50 per share.
Research and development expense rose to $173.3 million from $133.1 million.
Arrowhead reported fiscal 2026 first-quarter results for the period ended December 31, 2025, with revenue of $264.0 million, up from $2.5 million a year earlier. The company swung to net income attributable to Arrowhead of $30.8 million, or $0.22 per diluted share, from a loss of $173.1 million, or $1.39 per share, in the prior-year quarter.
Revenue was $264.0 million for the quarter ended December 31, 2025, compared with $2.5 million for the same quarter a year earlier.
Net income attributable to Arrowhead was $30.8 million, or $0.22 per diluted share, compared with a loss of $173.1 million, or $1.39 per share.
The company closed two concurrent public offerings with gross proceeds totaling $930 million and received a $200 million upfront payment from Novartis.
Arrowhead Pharmaceuticals issued $700 million of 0.00% convertible senior notes due January 15, 2032, including $75 million from the underwriters' full exercise of their over-allotment option. The company also spent approximately $47.9 million on capped call transactions, which are expected to reduce potential dilution from future conversions of the notes.
Notes issued January 12, 2026: $700 million principal, 0.00% interest rate, maturing January 15, 2032
Initial conversion price of approximately $87.07 per share; the company may settle conversions in cash, shares or a combination
Capped call transactions cost approximately $47.9 million, with a cap price of approximately $119.33 per share
Company may redeem notes on or after January 16, 2029 if the stock exceeds 130% of the conversion price under specified conditions
On January 7, 2026, Arrowhead Pharmaceuticals agreed to sell $625 million of 0.00% convertible senior notes due 2032, upsized from $500 million, and 3,100,776 common shares at $64.50 per share. Underwriters exercised their over-allotment options in full on January 8, 2026. The filing says the offerings add shares and potential conversion shares, which could dilute existing shareholders, and that proceeds are for general corporate purposes and may partly prepay its Sixth Street credit facility.
Convertible notes: $625 million principal, 0.00% interest, maturing January 15, 2032; initial conversion price about $87.07 per share, a premium of about 35.0% to the $64.50 stock offering price.
Common stock: 3,100,776 shares at $64.50 each, plus a 456,116-share option exercised in full on January 8, 2026.
Expected net proceeds with options: about $681.3 million from the notes and $216.6 million from the stock; closings expected January 12, 2026 (notes) and January 9, 2026 (stock).
About $42.8 million of note proceeds will fund capped call transactions; the remainder is for general corporate purposes, and a portion may prepay Sixth Street Lending Partners loans.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Arrowhead Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →